From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Orlistat and Weight Loss in Adolescents

Among teens receiving apparently intense behavioral interventions, orlistat lowered BMI more than placebo did.

Orlistat, an inhibitor of gastrointestinal fat absorption used for promoting weight loss in adults, was approved for use in adolescents in 2003, partly based on results from this randomized trial. The manufacturer of orlistat contributed to the study design, data analysis, and manuscript preparation.

Researchers randomized 539 obese adolescents (age range, 12–16) to receive orlistat (120 mg, 3 times daily) or placebo for 1 year. All participants received instruction in maintaining hypocaloric diets and regular exercise; behavioral modification techniques were used to change eating habits. About 65% of each group completed the trial, but all 533 subjects who had at least one follow-up assessment were included in the analyses.

At 12 weeks, mean body-mass index had decreased by 1 unit among orlistat recipients and by 0.5 units among controls. At 1 year, mean BMI was roughly 0.6 units lower than baseline among orlistat subjects and about 0.2 units higher than baseline among controls, and BMI had decreased by ≥5% among significantly more orlistat subjects than controls (27% vs. 16%). Gastrointestinal adverse events were more common in the orlistat group, ranging from 9% with fecal incontinence to 50% with fatty/oily stool.

Comment: These findings are intriguing, but they are difficult to translate into routine practice for many reasons: A large proportion of subjects did not complete the study; the behavioral interventions were intense (as suggested by the impressive weight loss in one sixth of controls); the side effects were considerable; and the medication is expensive (US$170/month wholesale, according to an editorialist) and would have to be taken during school.

— Thomas L. Schwenk, MD

Published in Journal Watch General Medicine June 28, 2005

Citation(s):

Chanoine J-P et al. Effect of orlistat on weight and body composition in obese adolescents: A randomized controlled trial. JAMA 2005 Jun 15; 293:2873-83.

Joffe A. Pharmacotherapy for adolescent obesity: A weighty issue. JAMA 2005 Jun 15; 293:2932-4.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Related Content

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2005. Massachusetts Medical Society. All rights reserved.